Integrating radioembolization ( 90Y Microspheres) into current treatment options for liver tumors: Introduction to the international working group report

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 1, 2012, Pages 81-90

  Kennedy, Andrew ^a,b,c   Coldwell, Douglas ^d   Sangro, Bruno ^e,f   Wasan, Harpreet ^g   Salem, Riad ^h  

^a Wake Radiology Oncology   (United States)

^b North Carolina State University   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f UNIVERSITY OF NAVARRA   (Spain)

^g HAMMERSMITH HOSPITAL   (United Kingdom)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

chemoradiation; hepatic; metastases; SIRT; Yttrium 90

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLASS Y 90; IRINOTECAN; MICROSPHERE; OXALIPLATIN; RESIN Y 90; SORAFENIB; UNCLASSIFIED DRUG; YTTRIUM 90;

ADJUVANT CHEMOTHERAPY; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; HEPATIC ARTERY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER RESECTION; METASTASIS; MONOTHERAPY; SOLID TUMOR;

CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; EMBOLIZATION, THERAPEUTIC; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MICROSPHERES; SURVIVAL RATE; YTTRIUM RADIOISOTOPES;

EID: 84856304395     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181ec60b8     Document Type: Article

References (162)

1. Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106:1624-1633.
2. Kasper HU, Drebber U, Dries V, et al. Liver metastases: incidence and histogenesis [in German]. Z Gastroenterol. 2005;43:1149-1157. (Pubitemid 41584817)
3. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg. 1995;19:76-82.
4. Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001;136:950-955. (Pubitemid 32729559)
5. Pentheroudakis G, Fountzilas G, Bafaloukos D, et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat. 2006;97:237-244. (Pubitemid 43945754)
6. Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244:897-907. (Pubitemid 44808622)
7. McMillan DC, McArdle CS. Epidemiology of colorectal liver metastases. Surg Oncol. 2007;16:3-5. (Pubitemid 46887664)
8. Leporrier J, Maurel J, Chiche L, et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465-474.
9. Sahani DV, Kalva SP. Imaging the liver. Oncologist. 2004;9: 385-397. (Pubitemid 39014550)
10. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224:748-756. (Pubitemid 34919808)
11. Erichsen R, Jepsen P, Jacobsen J, et al. Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985-2004. Eur J Gastroenterol Hepatol. 2008;20:104-110.
12. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDGPET). Ann Surg. 2004;240:438-447.
13. Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240: 1027-1034.
14. Delis SG, Dervenis C. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol. 2008;14:3452-3460.
15. Elias D, Sideris L, Pocard M, et al. Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation). Ann Surg Oncol. 2005;12:298-302. (Pubitemid 40616494)
16. Rohren EM, Paulson EK, Hagge R, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med. 2002;27: 550-555. (Pubitemid 36372892)
17. Mullhaupt B, Junker C, Wuest E, et al. Mortality from primary liver cancer in Switzerland from 1975 to 1994. Swiss Med Wkly. 2008;138:313-316. (Pubitemid 351871425)
18. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;40:745-750. (Pubitemid 29114292)
19. Deuffic S, Poynard T, Buffat L, et al. Trends in primary liver cancer. Lancet. 1998;51:214-215.
20. Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997;50:1142-1145.
21. DeVos IH, Goldberg D, Hole DJ, et al. Trends in primary liver cancer. Lancet. 1998;51:215-216.
22. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25:3771-3777. (Pubitemid 43980472)
23. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160:3227-3230.
24. LiverMetSurvey. European registry of hepatic metastasis of colorectal origin [LiverMetSurvey Web site]. Available at: http://www.livermetsurvey.org. (Accessed September 2, 2009).
25. Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med. 2005;56: 139-156. (Pubitemid 40299777)
26. Yan LN, Chen XL, Li ZH, et al. Perioperative management of primary liver cancer. World J Gastroenterol. 2007;13: 1970-1974.
27. Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45:838-847. (Pubitemid 44423130)
28. Liu YM, Qin H, Wang CB, et al. Comparison of therapeutic effectiveness of combined interventional therapy for 1126 cases of primary liver cancer. World J Gastroenterol. 2006;12:5060-5063. (Pubitemid 44323280)
29. Vlastos G, Smith DL, Singletary SE, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol. 2004;11:869-874.
30. Khatri VP, Chee KG, Petrelli NJ. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol. 2007;16:71-83. (Pubitemid 46880341)
31. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200. (Pubitemid 40781071)
32. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-657.
33. Ahmad A, Chen SL, Bilchik AJ. Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases. Arch Surg. 2007;142:526-531. (Pubitemid 46956397)
34. Cummings LC, Payes JD, Cooper GS, et al. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109:718-726. (Pubitemid 46233233)
35. Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transpl Surg. 1999;5:65-80. (Pubitemid 29037357)
36. Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist. 2001;6:81-91. (Pubitemid 32155818)
37. Borner MM, Castiglione M, Bacchi M, et al. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 1998;9:535-541. (Pubitemid 28270642)
38. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer. 1997;80:1179-1187.
39. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
40. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liveronly metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23: 9243-9249.
41. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25: 1670-1676. (Pubitemid 46797946)
42. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15: 933-939. (Pubitemid 39004350)
43. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016. (Pubitemid 351392040)
44. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2006;25:CD002092.
45. Deutsch E, Ezra P, Mangoni M, et al. Radiotherapy for localized rectal cancer. Ann Oncol. 2007;18(suppl 9):ix105-ix113.
46. Kavanagh BD, Schefter TE, Cardenes HR, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006;45:848-855. (Pubitemid 44423131)
47. 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552-1563. (Pubitemid 39601873)
48. Gray B, van Hazel G, Hope M, et al. Randomised trial of SIRSpheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711-1720. (Pubitemid 34105661)
49. Moroz P, Anderson J, Van Hazel G, et al. Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol. 2001;78:248-252. (Pubitemid 33097055)
50. Goin JE, Dancey JE, Hermann GA, et al. Treatment of unresectable metastatic colorectal carcinoma to the liver with intrahepatic Y-90 micro-spheres: dose-ranging study. World J Nucl Med. 2003;2:216-225.
51. van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78-85. (Pubitemid 39536508)
52. van Hazel G, Turner D, Gebski V. Impact of (90)Y resin microspheres on health-related quality of life (HRQoL) in patients with colorectal cancer (CRC) liver metastases receiving first-line chemotherapy. Poster presented at: The American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2009; Alexandria, VA. Abstract 419.
53. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with selective internal radiation therapy (SIR-Spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;5:132.
54. Sharma R, van Hazel G, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using Yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099-1106. (Pubitemid 46596762)
55. 90Yttrium resin microspheres alone in unresectable, heavily pre-treated colorectal liver metastases: results of a phase II trial. American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2008;26(suppl): Abstract 4078.
56. 90Yttrium SIR-Spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. In Vivo. 2006;20:711-714. (Pubitemid 46061605)
57. Pennington KL, Gulec SA, Bruetman D, et al. Phase II trial of multiagent chemotherapy combined with Y-90 microsphere selective internal radiation therapy (chemo-SIRT) in patients with colorectal cancer liver metastases. American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2008;26(suppl):Abstract 15011.
58. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009;115:1849-1858.
59. Seidensticker M, Rühl R, Kraus P, et al. Radioembolization with yttrium-90 resin microspheres as a salvage treatment for refractory liver-dominant colorectal metastases: a matched-pair analysis. ECCO 15/34th ESMO. Eur J Cancer Suppl. 2009;7: 343. Abstract 6071.
60. Van den Eynde M, Hendlisz A, Peeters M, et al. Prospective randomized study comparing intra-arterial injection of yttrium-90 resin microspheres with protracted IV 5FU continuous infusion versus IV 5FU continuous infusion alone for patients with liverlimited metastatic colorectal cancer refractory to standard chemotherapy. American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2009;27(suppl 7s):Abstract 4096.
61. Van den Eynde M, Flamen P, El Nakadi I, et al. Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med. 2008;33:697-699.
62. van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of 5-fluourouracil-refractory patients with liver metastases from colorectal cancer using yttrium 90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009;27:4089-4095.
63. Gray B, Anderson J, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg. 1992;62:105-110.
64. Stubbs R, Cannan R, Mitchell A, et al. An initial experience with selective internal radiation therapy (SIRT) for non-resectable colorectal liver metastases. Gastrointest Cancer. 1999;3:135-143.
65. Gray B, van Hazel G, Buck M, et al. Treatment of colorectal liver metastases with SIR-Spheres plus chemotherapy. Gastrointest Cancer. 2000;3:249-257.
66. Stubbs R, Cannan R, Mitchell A. Selective internal radiation therapy with yttrium-90 microspheres for extensive liver metastases. J Gastrointest Surg. 2001;5:294-302. (Pubitemid 33652075)
67. Stubbs R, Wickremesekera S. Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. HPB (Oxford). 2004;6:133-139. (Pubitemid 39248172)
68. 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004;45:1892-1897. (Pubitemid 47618448)
69. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16:937-945. (Pubitemid 40993516)
70. 90Y-microspheres for colorectal liver metastases: single-centre experience with 100 patients. Aust N Z J Surg. 2006;76:696-703. (Pubitemid 44154740)
71. 90Y-microsphere brachytherapy for unresectable colorectal metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65: 412-425.
72. Boppudi S, Wickremesekera S, Nowitz M, et al. Evaluation of the role of CT in the assessment of response to selective internal radiation therapy in patients with colorectal liver metastases. Australas Radiol. 2006;50:570-577. (Pubitemid 44748082)
73. Murthy R, Eng C, Krishnan S, et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007;18: 1588-1591. (Pubitemid 350151878)
74. Jakobs TF, Hoffmann R, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187-1195.
75. Tan TH, Kosmider S, Yip D, et al. Clinical experience of selective internal radiation therapy in combination with systemic chemotherapy as first-line therapy in patients with unresectable hepatic metastases from colorectal cancer. 2008 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2008;26(suppl):Abstract 15080.
76. Hong K, McBride JD, Georgiades CS, et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009;20: 360-367.
77. 90Y-microsphere treatment of colorectal liver metastases. 20th International Congress on Anti Cancer Treatment (ICACT) 2009:Abstract IC/AB159.
78. Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol. 2009;32:1179-1186.
79. Campbell JM, Wong CO, Muzik O, et al. Early dose response to Yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography. Int J Radiat Oncol Biol Phys. 2009;74:313-320.
80. Shepherd FA, Rotstein LE, Houle S, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer. 1992;70: 2250-2254.
81. Lau WY, Leung WT, Ho S, et al. Treatment of inoperative hepatocellular carcinoma with intra-arterial yttrium-90 microspheres: a phase 1 and 2 study. Br J Cancer. 1994;70:994-999. (Pubitemid 24331102)
82. 90Yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583-592. (Pubitemid 28104228)
83. 90Ymicrospheres. J Nucl Med. 2000;41:1673-1681.
84. Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of cisplatin versus 90-yttrium microspheres (Therasphere). Psychooncology. 2004;13:73-79. (Pubitemid 38247763)
85. 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639. (Pubitemid 44431160)
86. Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66: 792-800. (Pubitemid 44436697)
87. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81. (Pubitemid 351171043)
88. El Fouly A, Ertle J, Antoch G, et al. Response rate according to WHO, RECIST and EASL criteria after radioembolization of yttrium-90 glass microspheres in advanced hepatocellular carcinoma: a European pilot phase II study. 44th Annual Meeting of the European Association for the Study of the Liver (EASL). J Hepatol. 2009;20(suppl 1):S22. Abstract 51.
89. Woodall CE, Scoggins CR, Ellis SF, et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg. 2009;208:375-382.
90. Lau W, Ho S, Leung C, et al. What determines survival duration in hepatocellular carcinoma treated with intraarterial yttrium-90 microspheres? Hepatogastroenterology. 2001;48:338-340. (Pubitemid 32391562)
91. 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(suppl 1):S107-S110. (Pubitemid 38240109)
92. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(suppl 1):S194-S205. (Pubitemid 39423388)
93. Goin JE, Dancey JE, Roberts CA, et al. Comparison of postembolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med. 2004;3:49-56.
94. Salem R, Lewandowski R, Roberts C, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15:335-345. (Pubitemid 38451976)
95. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16:195-203. (Pubitemid 40322292)
96. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16:205-213. (Pubitemid 40322293)
97. Kulik LM, Atassi B, Van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: down-staging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006;94:572-586. (Pubitemid 44851918)
98. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:1375-1382. (Pubitemid 47628904)
99. D'Avola D, Iñarrairaegui M, Bilbao JI, et al. Extended survival in patients with unresectable advanced hepatocellular carcinoma treated using radioembolization. Poster presented at: The 2nd International Liver Cancer Association Meeting 2008. Abstract P-139.
100. Minocha J, Kulik L, Ibrahim SM, et al. Prognostic value of lung shunting fraction in patients undergoing Yttrium-90 radioembolization for HCC. Poster presented at: 2nd International Liver Cancer Association Meeting; September 2008. Abstract P-115.
101. 90Y-glass microspheres for hepatocellular carcinoma with macrovascular invasion: preliminary results. Poster presented at: 2nd International Liver Cancer Association meeting; September 2008. Abstract P-142.
102. 90Y-resin microspheres: mid-term results in a single institute experience. Paper presented at: the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Conference 2009. Abstract 1905.4.
103. Iñarrairaegui M, D'Avola D, Rodriguez M, et al. Prognostic factors among patients with hepatocellular carcinoma (HCC) treated by Y90-radioembolization (Y90-RE). 44th Annual Meeting of the European Association for the Study of the Liver (EASL). J Hepatol. 2009;20(suppl 1):S291. Abstract. 795.
104. Reardon KA, McIntosh AF, Shilling AT, et al. Treatment of primary liver tumors with Yttrium-90 microspheres (Thera- Sphere) in high risk patients: analysis of survival and toxicities. Technol Cancer Res Treat. 2009;8:71-77.
105. Riaz A, Lewandowski RJ, Ryu RK, et al Chemoembolization vs comparison of toxicity, imaging response and long-term outcomes in 100 TACE vs 104 Y90 patients. Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26:Abstract. 215.
106. Scanlon T, Riaz A, Lewandowski RJ, et al. Treatment of solitary HCC: comparison of TACE and Y90 radioembolization. Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26:Abstract. 195.
107. Khanna V, Dhanasekaran R, Kooby DA, et al. Comparison of survival benefits of conventional TACE, precision TACE (drug eluting beads with doxorubicin) and Yttrium-90 radioembolization (SIR-spheres) for unresectable HCC. The Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26:S84. Abstract. 217.
108. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-1928.
109. Moreno Luna LE, Sanchez W, James AC, et al. Survival of patients treated with Yttrium-90 radioembolisation vs chemoembolisation for unresectable hepatocellular carcinoma. Paper presented at: The 3rd International Liver Cancer Association (ILCA) Annual Conference 2009. Abstract O-033.
110. 90Y radioembolization using resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. Poster presented at: American Association for the Study of the Liver (AASLD) 2009. Abstract 1730.
111. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-5742.
112. 90Y-labeled resin microspheres in unresectable hepatocellular carcinoma (HCC): results from a European multi-center evaluation. Poster presented at: American Association for the Study of the Liver (AASLD) 2009. Abstract 1712.
113. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.
114. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119-2128.
115. Saxena A, Bester L, Chua TC, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17:484-491.
116. Coldwell D. Treatment of unresectable nodular cholangiocarcinoma with yttrium-90 microspheres. Ann Oncol. 2006;17(suppl 6):vi56. Abstract P-102.
117. Khanna V, Dhanasekaran R, Barron BJ, et al. Yttrium-90 radioembolization (SIR-spheres) for cholangiocarcinoma: preliminary study. The Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26: S116-S117. Abstract. 309
118. Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar Yttrium-90 radioembolization. Ann Surg Oncol. 2009;16: 1587-1596.
119. Meranze SG, Bream PR, Grzeszczak E, et al. Phase II clinical trial of yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. Poster presented at: Society of Interventional Radiology (SIR) 32nd Annual Scientific Meeting 2007. Abstract. 422.
120. King J, Quinn R, Glenn D, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921-929.
121. 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247: 1029-1035. (Pubitemid 351770424)
122. Kalinowski M, Dressler M, König A, et al. Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009;79:137-142.
123. 90Y-microsphere brachytherapy. Annual American Brachytherapy Society Meeting. Brachytherapy. 2006;5:103. AbstractP-75.
124. 90Y-microsphere radioembolisation is effective in controlling hepatic metastases from neuroendocrine primary cancers. Paper presented at: the Emerging Trends in Radioembolization using Microspheres, 3rd Annual Clinical Symposium; May 4-5, 2007.
125. 90- microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271-279.
126. Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008;19:145-151.
127. Granberg D, Garske U, Welin S, et al. Selective internal radiation therapy in patients with carcinoid liver metastases. Acta Oncologica. 2008;47:1169-1171.
128. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol. 2007;18:621-628. (Pubitemid 46661173)
129. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19:683-690.
130. Coldwell D, Kennedy A, Nutting C. The use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2007;69: 800-804. (Pubitemid 47418394)
131. Gulec SA, Wheeler J, Pennington K, et al. Chemotherapy with Yttrium-90 microsphere selective internal radiation treatment and selective external radiation treatment in patients with metastatic pancreatic cancer. J Interv Oncol. 2009;2:84-92.
132. Murthy R, Mutha P, Lee JH, et al. Yttrium-90-labeled microsphere radioembolotherapy of liver-dominant metastases from thoracic malignancies. J Vasc Interv Radiol. 2008;19: 299-300.
133. Gulec SA, Pennington K, Hall M, et al. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol. 2009;7:6.
134. Kennedy A, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest. 2009;27:682-690.
135. Dhanasekaran R, Khanna V, Lawson D, et al. Survival benefits of Yttrium-90 radioembolization (SIR-spheres) for hepatic metastasis from melanoma: preliminary study. Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26:S65. Abstract. 167.
136. Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Selective internal radiation therapy (SIRT) as salvage therapy for uveal melanoma (UM) hepatic metastases. 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2009;27(suppl 7 s):Abstract 9066.
137. Herba MJ, Thirlwell MP. Radioembolization for hepatic metastases. Semin Oncol. 2002;29:152-159. (Pubitemid 34297286)
138. Lim L, Gibbs P, Yip D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J. 2005;35:222-227. (Pubitemid 40529583)
139. Wong C, Qing F, Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]Fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol. 2005;16:1101-1106. (Pubitemid 41177123)
140. Wong CY, Savin M, Sherpa KM, et al. Regional Yttrium-90 microsphere treatment of surgically unresectable and chemotherapy- refractory metastatic liver carcinoma. Cancer Biother Radiopharm. 2006;21:305-313. (Pubitemid 44689684)
141. 90Y microspheres-safety, efficacy, and survival. Radiol. 2008;247: 507-515.
142. Sato KT, Omary RA, Takehana C, et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol. 2009;20:1564-1569.
143. Lewandowski RJ, Riaz A, Ryu RK, et al. Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study. J Vasc Interv Radiol. 2009;20: 1557-1563.
144. Yu M, Lewandowski RJ, Wong CO, et al. Yttrium-90 (SIRSpheres) treatment for metastatic cancer to the liver: midterm results. Paper presented at: Society of Interventional Radiologists (SIR) 31st Annual Scientific Meeting; March 2006; Toronto, ON. Abstract 17.
145. Janssen J, Quinn R, Morris D, et al. Clinical side effects associated with the administration of Y90 SIR-spheres. Paper presented at: 36th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine; April 2006; Perth, WA. Abstract 53.
146. Wang SC, Ho YY, Leung FP, et al. Outcomes following selective internal radiation therapy with SIR-spheres in non-resectable hepatic malignancy. World Conf Interv Oncol. 2006. Abstract 8145.
147. Cianni R, Satarelli A, Notarianni E, et al. Radioembolism (Yttrium-90) of hepatic liver metastases. A preliminary experience. Cardiovasc Interv Radiol. 2006. Abstract 49.1.9.
148. 90Yttrium resinmicrospheres. Eur Radiol. 2007; 17:1320-1330. (Pubitemid 46691963)
149. Gulec SA, Mesoloras G, Dezarn WA, et al. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Translat Med. 2007;5:15.
150. 90Yttrium microspheres for nonresectable liver cancer: the University of Connecticut Health Center experience. Conn Med. 2007;71:523-528.
151. Alonso-Burgos A, Iñarrairaegui M, Sangro B, et al. Radioembolisation of liver tumors: determinants of antitumor effect using Y90-labeled resin microspheres. Poster presented at: Cardiovascular and Interventional Radiology of Europe (CIRSE) Meeting 2008; Copenhagen, Denmark. Abstract P-74.
152. Ruehl R, Seidensticker M, Denecke T, et al. Selektive interne radioembolisation (SIRT) mit mikrosphären bei extensiven, therapierefraktären, progredienten lebermalignomen [in French]. Deutsche Gesellschaft für Nuklearmedizin. 2008. Abstract.
153. Stuart JE, Tan B, Myerson RJ, et al. Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: Initial outcomes. J Vasc Interv Radiol. 2008;19:1427-1433.
154. Hoffmann RT, Jakobs TF, Kubisch C, et al. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver diseaseis it feasible? Eur J Radiol. 2010;74:199-205.
155. Johnson DW, Mori KH, O'Laughlin SR, et al. Safety and efficacy of Yttrium-90 labeled microsphere radiation treatment for hepatic metastases. Northeast Florida Med. 2009;60:37-41.
156. Whitney R, Tatum C, Hahl M, et al. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J Surg Res. (In press).
157. Seaton T, Naji M, Tait P, et al. Selective internal radiotherapy for unresectable liver tumours: follow up of 74 cases. Paper presented at: European Association of Nuclear Medicine (EANM) Conference; October 10-14, 2009; Barcelona, Spain. Abstract OP374.
158. Jiao LR, Szyszko T, Al-Nahhas, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol. 2007;33:597-602. (Pubitemid 46746540)
159. 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun. 2007;28:15-20. (Pubitemid 44949683)
160. Sharma RA, Wasan HS, Love SB, et al. FOXFIRE: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer. Clin Oncol (Royal Coll Radiol). 2008;20:261-263.
161. Rose SC, Gulec SA. Yttrium 90 radioembolization therapy: ongoing clinical trials. J Interv Oncol. (In press).
162. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. The Cancer Journal. 2010;16:163-175.